Coleman Mark 4
4 · Axsome Therapeutics, Inc. · Filed May 29, 2025
Insider Transaction Report
Form 4
Coleman Mark
Director
Transactions
- Sale
Common Stock
2025-05-28$103.43/sh−3,750$387,863→ 46,637 total - Sale
Common Stock
2025-05-27$105.47/sh−3,750$395,513→ 50,387 total
Holdings
- 403,856(indirect: See Footnote)
Common Stock
Footnotes (5)
- [F1]Represents the sale of underlying shares of previously exercised stock options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $104.75 and $106.50.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $102.71 and $104.38.
- [F5]Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.